Fidaxomicin for <i>Clostridium difficile</i> Colitis in a Peritoneal Dialysis Patient with Underlying Mitochondriopathy

Windpessl, Martin; Wallner, Manfred

doi:10.3747/pdi.2013.00040

Cited by 2 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has a narrow spectrum activity mostly directed towards Gram-positive anaerobes 10 and has been successfully used in PD patient. 11 Continuing PD exchange with dextrose during an active colitis may rise some concerns given its potential effect in favouring peritoneal bacterial growth. However, there are no definitive recommendations to this regard and benefit of stopping PD exchange need to be balanced with the risk of central venous catheter placement and its infective risk during a systemic infection and of inability to tolerate HD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clostridium difficile colitis and peritoneal dialysis associated peritonitis: ‘Difficile’ treatment considerations

et al. 2022

View full text Add to dashboard Cite

Peritoneal dialysis (PD) associated peritonitis is the leading cause of PD discontinuation and haemodialysis transfer. Current guidelines strongly recommend prompt initiation of empiric broad-spectrum intraperitoneal antibiotics, with suspected peritonitis. Clostridium difficile colitis is one of the most common healthcare-associated infections, with increased morbidity and mortality among end-stage kidney disease patients. Clinical presentation is mainly characterised by diarrhoea of varying severity, which may eventually evolve into toxic megacolon and paralytic ileus. However, PD patients with Clostridium difficile infection (CDI) may also have colitis-triggered peritonitis, presenting challenging scenario for antibiotic treatment strategy, since broad-spectrum antibiotics against peritonitis may worsen CDI-related colitis, while inappropriate or discontinuation of antibiotic therapy may worsen peritonitis. Currently, guidelines on peritonitis management do not include such challenging clinical situations, although increasingly common. We herein describe a case of a patient, with culture-negative PD associated peritonitis and CDI, presenting with diarrhoea, abdominal pain and cloudy effluent.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It has a narrow spectrum activity mostly directed towards Gram-positive anaerobes 10 and has been successfully used in PD patient. 11…”

Section: Discussionmentioning

confidence: 99%

Clostridium difficile colitis and peritoneal dialysis associated peritonitis: ‘Difficile’ treatment considerations

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, our case occurred in 2013, when access to fidaxomicin and clinical experience of its use were limited. Today, fidaxomicin has demonstrated efficacy and safety in the treatment of CDI, including a previously published case study describing the successful treatment of severe CDI following prior failure of metronidazole and vancomycin in a 49-year-old patient undergoing peritoneal dialysis [32]. However, there are currently limited clinical data for fidaxomicin treatment of the more serious PMC.…”

Section: Case Reportmentioning

confidence: 99%

A Case Report of Pseudomembranous Colitis Resulting FromClostridium difficileInfection Successfully Treated With Fidaxomicin

et al. 2016

View full text Add to dashboard Cite

show abstract

Fidaxomicin for Clostridium difficile Colitis in a Peritoneal Dialysis Patient with Underlying Mitochondriopathy

Cited by 2 publications

References 7 publications

Clostridium difficile colitis and peritoneal dialysis associated peritonitis: ‘Difficile’ treatment considerations

Clostridium difficile colitis and peritoneal dialysis associated peritonitis: ‘Difficile’ treatment considerations

A Case Report of Pseudomembranous Colitis Resulting FromClostridium difficileInfection Successfully Treated With Fidaxomicin

Contact Info

Product

Resources

About